Brought to you by 
Genzyme gets rights to Alnylam's RNAi candidates for ATTR; rights expanded in new deal
27 May 2021
Executive Summary
RNAi therapeutics developer Alnylam Pharmaceuticals Inc. has granted Sanofi’s Genzyme Corp. exclusive rights to develop and sell two of its candidates targeting transthyretin (TTR; a protein normally produced by the liver) to treat transthyretin-mediated amyloidosis (ATTR). Sanofi’s rights cover Japan and other Asia-Pacific countries, including Korea, Taiwan, China, India, Australia, and New Zealand.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme gets rights to Alnylam's RNAi candidates for ATTR; rights expanded in new deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice